Adbry shows long-term efficacy in atopic dermatitis

Key takeaways:

• Full results of the long-term ECZTEND trial of Adbry for atopic dermatitis were announced at the Fall Clinical Dermatology Conference.
• Of 1,672 patients, 92.9% achieved a reduction of at least 75% in EASI score.

LEO Pharma presented full results from its long-term trial of Adbry for atopic dermatitis at the Fall Clinical Dermatology Conference, according to a company press release.

The phase 3, long-term, 5-year, open-label, single-arm ECZTEND extension trial included 1,672 patients aged 12 years and older who previously participated in one of the nine ECZTRA trials and evaluated the safety and efficacy of Adbry (tralokinumab-ldrm, LEO Pharma).

In 92.9% of patients, a reduction of at least 75% in EASI score was found from baseline to week 248, with 66.7% achieved an IGA score of 0 or 1.

“Dermatologists always want to know about long-term efficacy and safety of medications they use for their patients, especially biologics,” Andrew Blauvelt, MD, MBA, founder of Blauvelt Consulting and international coordinating investigator of the ECZTEND trial, told Healio. “These current ECZTEND results answer these questions about tralokinumab, a drug that had previously been shown to be safe and effective for patients with atopic dermatitis when used for shorter periods of time.”

Patients also experienced significant improvements in itch, sleep and quality of life.

“Impressively, the final 6-year results for the ECZTEND study show that tralokinumab-treated atopic dermatitis patients continue to experience great benefits of the drug over long periods of time, and that the drug continues to be very safe,” Blauvelt said. “These results should reassure both dermatology practitioners as well as patients that tralokinumab offers a great benefit-risk profile.”